WINDSOR, ON / ACCESSWIRE / March 9, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known Biotech stocks, would like to announce some recent breakthroughs in the development of new cancer treatments, and the companies that play in the field.
Chemotherapy and other key cancer treatments have so far only been effective in the elimination of cancer cells that are at the initial stages. Propanc Health Group Corp (OTC: PPCH) is a Company developing a revolutionary new drug, which in its trial stages, set to provide a lasting treatment option for advanced cancer cells. It will also prevent the re-growth of cancer cells through metastasis.
Since 2007, Propanc, an innovative biopharmaceutical company, has been working with extensive drug development and oncology and clinical experts, Professor Klaus Kutz and Dr. Julian Kenyon whose combined experience of more than 60 years in medicine has been critical in the research and development of PRP anti-cancer treatment.
By focusing on metastasis (cancer spreading) as the main and most difficult challenge to treating cancer, Propanc's PRP is designed to ensure that malignant cancer cells cannot transfer to secondary locations and seed new tumors. Its multi-functional cancer fighting properties ensure enhanced production of the naturally occurring protein E-Cadherin to prevent metastasis, prevent the transformation of epithelial cells into mesenchymal cells through epithelial-to-mesenchymal transition (EMT), and prevents cancer cell re-growth, hence preventing the spreading of cancer to vital organs of the body. By restoring E-Cadherin levels, transition of epithelial cells to mesenchymal cells is inhibited in a process that prevents the growth of invasive cells travelling to other parts of the body through the lymphatic system or blood into surrounding tissues. PRP works by altering several critical pathways for cancer cells that otherwise lead to the growth of malignant tumors.
Since the technology behind PRP uses the body's own natural proteolytic enzymes, there is significantly less risk of severe, or even serious side effects on the body compared to current treatments. PRP's targeted approach to killing cancer cells and preventing metastasis may be complementary, or in some cases a preferred option to chemotherapy, which in addition to killing cancer cells, also damages healthy cells in the body. With targeted cancer cell treatment, Propanc's PRP proteolytic proenzymes can potentially be used for long-term treatment.
Dr. Kenyon and Professor Kutz believe that the cure for cancer lies not in the shrinking of tumor cancer cells but in their entire elimination to prevent regeneration. Current treatments are failing to provide a lasting solution since shrink the tumors and leaving them harmless in the body does not completely kill all cancer cells hence the treatment is only a temporary solution.
At pre-clinical stage, Propanc will initially target colorectal and pancreatic cancer tumors in a two-step process of resolving identified tumors and preventing their spread through metastasis. By seeking to test, approve, and patent PRP, Propanc aims to provide its target market with a safe and highly effective treatment that could address later stage cancers.
PRP and PRP-DCM anti-cancer treatments explore a vast, untapped market that is in dire need for safe and effective folloup-up therapies for metastitic cancer. However, Propanc's approach to cancer treatment is still fairly new in the pharmaceuticals market and this is a factor that has investors undervaluing the company.
Many retail Investors do not yet know the many strides oncology medicine has made in the past 2 years; it can only be described as a quantum leap. In addition to the many advances made in proenzymes, many newer treatments utilize the body's own immune system to fight cancer cells, or immuno-oncology.
Immuno-oncology involves reprogramming the body's own T-cells (CAR-T) to "seek and destroy" cancer cells, typically with blood-based cancers. The preliminary work on the topic is most emblematic in the new IPO darlings of 2014-with triple digit returns since going public since then. Some standout names include:
Kite Pharma Inc., (NASDAQ: KITE)
Bluebird Bio Inc. (NASDAQ: BLUE)
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA)
Investors who are looking for exposure to the space with less risk are looking to names like Celgene Corp. (NASDAQ: CELG), Gilead Sciences (NASDAQ: GILD), and Biogen Inc. (NASDAQ: BIIB). These Biotech names have invested heavily in the smaller Bio's development programs in these CAR T drugs and would participate on potential upside they may have.
For further information, please contact:
1 (702) 575-9157
-------------------------------------------
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, The Wealthy Biotech Trader has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news & press releases, changes in corporate structure, or changes in share structure.
Our website and newsletter are for Entertainment purposes only. This newsletter is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold The Wealthy Biotech Trader, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The Wealthy Biotech Trader sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by The Wealthy Biotech Trader or an offer or solicitation to buy or sell any security.
COMPENSATION: The Wealthy Biotech Trader has been compensated four thousand dollars cash via bank wire by Propanc Health Group Inc. (OTC: PPCH) for a 1 month Investor Relations Contract. The Wealthy Biotech Trader does not own any shares of PPCH. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead The Wealthy Biotech Trader strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. The Wealthy Biotech Trader further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security's previous day closing price and the high of day price during our promotional coverage.
In preparing this publication, The Wealthy Biotech Trader has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, The Wealthy Biotech Trader and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. The Wealthy Biotech Trader is not responsible for any claims made by the companies advertised herein, nor is The Wealthy Biotech Trader responsible for any other promotional firm, its program or its structure.
SOURCE: The Wealthy Biotech Trader